Latest Financial Health News

Metgasco has obtained a A$500,000 bridging loan at 10% interest to cover immediate capital needs while advancing a broader debt restructuring plan.

Sheffield Resources has secured an additional US$10.15 million tranche on its senior loan facility for the Thunderbird Mineral Sands Mine, aimed at bolstering working capital. Ongoing negotiations to restructure debt add an element of financial uncertainty for the joint venture.

Electro Optic Systems (ASX:EOS) has launched a A$175 million capital raising to complete its MARSS acquisition and accelerate expansion in counter-drone and defence technologies, buoyed by a surge in Middle East orders.

Marimaca Copper Corp. reported a robust cash position of $147.7 million in Q1 2026, driven by a C$409 million equity raise, supporting ongoing development of its Marimaca Project in Chile.

Bhagwan Marine expects FY26 EBITDA between $44.5m and $46.5m, buoyed by Riverside Marine acquisition despite Middle East conflict causing project delays. The company highlights margin gains, disciplined costs, and rising recurring revenue as it advances integration and growth plans.

Temas Resources’ 2026 re-assays of 2022 drill samples at La Blache reveal material uplifts in vanadium, gallium, scandium, and chromium grades, strengthening the case for its proprietary Regenerative Chloride Leach technology.

WA Kaolin is seeking up to A$34.9 million through a fully underwritten entitlement offer aimed at restructuring its balance sheet, reducing shareholder loans, and funding operational improvements at its Wickepin kaolin project.

Energy Technologies Limited has secured nearly $2 million through a discounted share placement aimed at reducing debt and shoring up working capital amid ongoing financial restructuring.

AMA Group has initiated an on-market share buy-back program for up to 47.8 million shares, signalling confidence in its financial position and growth strategy without needing shareholder approval.

Judo Bank’s Q3 results show solid lending expansion, stable credit quality amid economic uncertainty, and reaffirmed FY26 guidance with a healthy capital buffer.

Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.